Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Janux Therapeutics Inc (JANX) has provided an update.
Janux Therapeutics, Inc. has experienced a shift in its Board of Directors, with Jay Lichter, Ph.D. stepping down and Ron Barrett, Ph.D. taking over as Chair. Additionally, Natasha Hernday and Eric Dobmeier have been appointed as new board members. Their terms will last until the annual meetings of stockholders in 2026 and 2027, respectively. Both Hernday and Dobmeier will receive a cash retainer, stock options, and restricted stock units as part of their compensation, with provisions for full vesting in the event of a company takeover. The company publicly announced these changes via a press release.
Learn more about JANX stock on TipRanks’ Stock Analysis page.
